In the present study, we demonstrated that the combination of HTGT and EMIQ exerts anti-obesity effects, comparable to those of mirabegron, a clinically available β3-AR agonist [32]. The gene discussed is ADRB3; the disease is obesity due to melanocortin 4 receptor deficiency.